Skip to main content

Table 8 Endoscopically detected ulcers in patients treated for arthritis, with and without aspirin

From: Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports

    Number of Incidence of events (%)   
Outcome/ comparisons Celecoxib daily dose Comparator and daily dose Trials Patients Celecoxib Comparator Relative riska (95% CI) NNTpb or NNHc (95% CI)
Analysis irrespective of aspirin use       
Celecoxib v placebo Any Placebo 2 1,737 3.9 2.2 1.8 (0.89–3.6)  
Celecoxib (200/400) v NSAID 200–400 mg NSAID to maximum daily 6 4,135 4.6 16.3 0.30 (0.24–0.37) a 8.6 (7.4–10) b
Celecoxib (any dose) v NSAID Any NSAID to maximum daily 6 4,565 4.5 16.3 0.29 (0.24–0.36) a 8.4 (7.3–10) b
Analysis without aspirin use       
Celecoxib v placebo Any Placebo 2 1,537 3.3 1.9 1.8 (0.79–3.9)  
Celecoxib (200/400) v NSAID 200–400 mg NSAID to maximum daily 5 3,053 4.5 17.6 0.28 (0.22–0.36) a 7.6 (6.5–9.1) b
Celecoxib (any dose) v NSAID Any NSAID to maximum daily 5 3,440 4.2 17.6 0.28 (0.22–0.36) a 7.5 (6.4–8.9) b
Analysis with aspirin use       
Celecoxib v placebo Any Placebo 2 200 7.9 4.1 1.7 (0.45–6.3)  
Celecoxib (200/400) v NSAID 200–400 mg NSAID to maximum daily 5 344 10.0 23.8 0.47 (0.27–0.83) a 7.3 (4.6–17) b
Celecoxib (any dose) v NSAID Any NSAID to maximum daily 5 387 9.9 23.8 0.48 (0.28–0.83) a 7.2 (4.7–16) b
  1. aRelative risk: bold indicates statistically significant difference. bNNTp (number-needed-to-treat to prevent one event) is indicated by bold. cNNH (number-needed-to-treat to harm one patient). CI, confidence interval; NSAID, nonsteroidal anti-inflammatory drug.